MassMutual Private Wealth & Trust FSB Sells 24,791 Shares of Pfizer Inc. (NYSE:PFE)

MassMutual Private Wealth & Trust FSB reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 134,089 shares of the biopharmaceutical company's stock after selling 24,791 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in Pfizer were worth $3,557,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of PFE. Thrivent Financial for Lutherans increased its stake in Pfizer by 2.8% during the 2nd quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company's stock worth $20,684,000 after buying an additional 20,140 shares during the period. ProShare Advisors LLC boosted its stake in Pfizer by 7.3% during the 2nd quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company's stock valued at $23,661,000 after acquiring an additional 57,825 shares during the last quarter. 1832 Asset Management L.P. increased its position in shares of Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company's stock worth $69,891,000 after purchasing an additional 2,487,919 shares during the last quarter. Fidelis Capital Partners LLC lifted its position in shares of Pfizer by 1.7% during the second quarter. Fidelis Capital Partners LLC now owns 24,568 shares of the biopharmaceutical company's stock worth $709,000 after purchasing an additional 412 shares during the last quarter. Finally, Gabelli Funds LLC grew its stake in Pfizer by 4.5% in the second quarter. Gabelli Funds LLC now owns 742,113 shares of the biopharmaceutical company's stock worth $20,764,000 after purchasing an additional 31,700 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Trading Up 0.9 %

NYSE:PFE traded up $0.23 during trading hours on Tuesday, reaching $26.53. 17,580,224 shares of the stock were exchanged, compared to its average volume of 32,181,537. The business has a 50-day moving average of $26.08 and a two-hundred day moving average of $27.98. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a market capitalization of $150.32 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.17) earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.48%. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PFE shares. Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price for the company. Finally, UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.